Novartis AG (NVS)
| Market Cap | 294.55B +33.7% |
| Revenue (ttm) | 56.67B +9.6% |
| Net Income | 13.98B +17.1% |
| EPS | 7.15 +21.8% |
| Shares Out | 1.91B |
| PE Ratio | 21.06 |
| Forward PE | 17.47 |
| Dividend | $3.08 (2.00%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 2,630,989 |
| Open | 153.37 |
| Previous Close | 155.08 |
| Day's Range | 153.16 - 154.81 |
| 52-Week Range | 97.72 - 170.46 |
| Beta | 0.50 |
| Analysts | Hold |
| Price Target | 144.00 (-6.51%) |
| Earnings Date | Apr 28, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $144.0, which is a decrease of -6.51% from the latest price.
News
Novartis (NVS) Reports Promising Phase III Results for Fabhalta in IgA Nephropathy
Novartis (NVS) Reports Promising Phase III Results for Fabhalta in IgA Nephropathy
Novartis: Fabhalta Cut Kidney Function Decline By 49.3% In IgAN
(RTTNews) - Novartis (NVS) reported final two-year results from its Phase 3 APPLAUSE IgAN study, showing that Fabhalta (iptacopan) slowed the decline in kidney function by 49.3% compared with placebo....
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically...
Novartis Agrees Up to $2B Excellergy Deal Amid Generic Pressure
Novartis Agrees Up to $2B Excellergy Deal Amid Generic Pressure
Novartis To Acquire Excellergy, Expanding Allergy Leadership
(RTTNews) - Novartis AG (NVS) has agreed to acquire Excellergy, Inc., a privately held biotech company developing next-generation anti-IgE therapies for allergic diseases.
Novartis to pay up to US$2 billion for US biotech firm Excellergy
Swiss drugmaker Novartis will buy California-based biotech company Excellergy in a deal worth up to US$2 billion, it said on Friday, extending its anti-allergy range and in line with plans to increase...
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
Novartis' acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company's existing allergy portfolio. It comes just a week after Novartis announced it is acquiring...
Novartis Expands Pipeline With $2 Billion Biotech Deal
Novartis Expands Pipeline With $2 Billion Biotech Deal
Novartis to Buy Biotech Excellergy for Up to $2 Billion
Novartis agreed to buy Excellergy, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion
Swiss pharma company Novartis said on Friday it will acquire California-based biotech company Excellergy in a deal worth up to $2 billion.
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
– Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction...
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism desi...
Novartis (NVS) Receives New Price Target from Morgan Stanley | NVS Stock News
Novartis (NVS) Receives New Price Target from Morgan Stanley | NVS Stock News
Sarepta Surges As It Takes On Novartis' $12 Billion Muscular Dystrophy Buyout
Sarepta stock popped Wednesday after the company reported promising results for its gene-silencing tech in two forms of muscular dystrophy.
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year's American Academy of Dermatology (AAD) Annual Meeting.
Novartis Agrees Up to $3 Billion Synnovation Breast Cancer Drug Deal
Novartis Agrees Up to $3 Billion Synnovation Breast Cancer Drug Deal
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potent...
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug
Novartis to acquire SNV4818 for $3 billion, targeting PIK3CA-mutated breast cancer with a potentially safer, precision-based approach. ... Full story available on Benzinga.com
Novartis (NVS) Acquires Innovative Cancer Therapy SNV4818 for $3 Billion
Novartis (NVS) Acquires Innovative Cancer Therapy SNV4818 for $3 Billion
Novartis (NVS) to Acquire Breast Cancer Drug from Synnovation for $3B
Novartis (NVS) to Acquire Breast Cancer Drug from Synnovation for $3B
Novartis Places $3 Billion Bet On Early Cancer Drug
Novartis Places $3 Billion Bet On Early Cancer Drug
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
SNV4818 is being evaluated in an early and mid-stage study for breast cancer and other advanced solid tumors, Novartis said.
Novartis to buy breast cancer drug candidate from Synnovation
Novartis said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further development ach...
Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Kα Inhibitor Program
WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology ...
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Basel, March 20, 2026 – Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a next-g...